Valuation: Novacyt

Market Cap 32.54M 37.13M 30.2M 27.75M 52.3M 3.58B 53.07M 360M 141M 1.75B 139M 136M 6.06B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 34.49M 39.36M 32.02M 29.42M 55.44M 3.8B 56.26M 381M 149M 1.86B 148M 145M 6.42B EV / Sales 2026 *
1.13x
EV / Sales 2027 * 1.07x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.72%
1 week-1.11%
Current month+9.35%
1 month+14.32%
3 months+19.01%
6 months+8.09%
Current year+6.42%
1 week 36.4
Extreme 36.4
41.6
1 month 33
Extreme 33
46.2
Current year 26.6
Extreme 26.6
86
1 year 26.6
Extreme 26.6
86
3 years 26.6
Extreme 26.6
137
5 years 26.6
Extreme 26.6
497.3
10 years 6.03
Extreme 6.03
1,270
Manager TitleAgeSince
Chief Executive Officer 53 30/04/2024
Director of Finance/CFO 44 31/12/2019
Chief Operating Officer - 31/10/2021
Director TitleAgeSince
Director/Board Member 75 02/07/2006
Director/Board Member 60 26/06/2017
Director/Board Member 44 01/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%-1.11% - - 37.13M
-3.47%-2.34%-38.31%-45.13% 621M
-7.63%-7.80%+198.36% - 526M
0.00%-11.70%-42.51%+0.66% 106M
+0.39%-2.62%+7.00%+57.58% 99.35M
Average -2.29%-6.12%+31.13%+4.37% 338M
Weighted average by Cap. -4.43%-5.22%+56.72%-26.92%

Financials

2026 *2027 *
Net sales 30.52M 34.84M 28.34M 26.04M 49.07M 3.36B 49.79M 338M 132M 1.64B 131M 128M 5.68B 34.86M 39.79M 32.36M 29.74M 56.04M 3.84B 56.86M 386M 151M 1.88B 149M 146M 6.49B
Net income - -
Net Debt 1.96M 2.23M 1.82M 1.67M 3.14M 215M 3.19M 21.63M 8.47M 105M 8.38M 8.2M 364M 4.84M 5.53M 4.5M 4.13M 7.78M 533M 7.9M 53.55M 20.96M 261M 20.74M 20.3M 901M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
23/07/26 GBX 37.73 -0.72% 629
22/07/26 GBX 38.00 0.00% 17,940
21/07/26 GBX 38.00 -8.65% 62,872
20/07/26 GBX 41.60 +4.00% 136,774
17/07/26 GBX 40.00 +4.85% 93,837

Annual profits - Rate of surprise